Latest SEC filings for CRISPR Therapeutics AG (CRSP) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
KASINGER JAMES R., listed as General Counsel and Secretary at CRISPR Therapeutics AG, reported an open-market sale of 3,182 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Kulkarni Samarth, listed as Director, Chief Executive Officer at CRISPR Therapeutics AG, reported an open-market sale of 10,020 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Prasad Raju, listed as Chief Financial Officer at CRISPR Therapeutics AG, reported an open-market sale of 3,708 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Patel Naimish (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Patel Naimish, listed as Chief Medical Officer at CRISPR Therapeutics AG, reported an open-market sale of 3,150 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Prasad Raju, listed as Chief Financial Officer at CRISPR Therapeutics AG, reported an open-market sale of 9,869 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
KASINGER JAMES R., listed as General Counsel and Secretary at CRISPR Therapeutics AG, reported an open-market sale of 3,450 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Kulkarni Samarth, listed as Director, Chief Executive Officer at CRISPR Therapeutics AG, reported an open-market sale of 10,349 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
CRISPR Therapeutics AG filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
KASINGER JAMES R., listed as General Counsel and Secretary at CRISPR Therapeutics AG, reported an open-market sale of 2,800 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Kulkarni Samarth, listed as Director, Chief Executive Officer at CRISPR Therapeutics AG, reported an open-market sale of 9,798 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
CRISPR Therapeutics AG filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Kulkarni Samarth, listed as Director, Chief Executive Officer at CRISPR Therapeutics AG, reported an open-market sale of 6,967 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
KASINGER JAMES R., listed as General Counsel and Secretary at CRISPR Therapeutics AG, reported an open-market sale of 2,112 CRSP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
CRISPR Therapeutics AG filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.